Abstract: Objective: To compare the efficacy and safety between ixekizumab and adalimumab in the treatment of moderate to severe plaque psoriasis. Methods: A retrospective study was conducted among patients with moderate-to-severe plaque psoriasis using ixekizumab or adalimumab from January 2020 to October 2022. Psoriasis lesion area and severity index (PASI), dermatologic quality of life index （DLQI） and adverse events were analyzed at baseline, 2, 4, 8, 12 and 24 week after administrating. Results: A total of 48 patients were analyzed in this study, including 31 patients in the ixekizumab treatment group and 17 patients in the adalimumab treatment group. Among the 48 patients, 37 were treated for 24 weeks, of which 25 were in the ixekizumab treatment group and 12 were in the adalimumab treatment group. PASI90 response rates in the ixekezumab group were 0%, 32.26%, 80.65% and 84.00% at 2, 4, 12 and 24 week after dosing, and PASI 100 response rates were 0%, 12.90%, 45.16% and 64.00%. The PASI 90 response rates were 0%, 5.88%, 47.06% and 66.67% and PASI 100 response rates were 0%, 5.88%, 23.53% and 25.00% in the adalimumab treatment group at 2, 4, 12 and 24 week. The median time to reach PASI 75 in the ixekizumab group was 4 weeks, that  of in the adalimumab group was 8 weeks.  No serious adverse reactions were observed in any of the patients. Conclusion: The short-term effect of ixekizumab were superior to adalimumab at improvement lesion severity as well as onset of action in the treatment of moderate to severe psoriasis vulgaris. The safety of the two drugs is comparable.

Key words: psoriasis, ixekizumab, adalimumab, efficacy evaluation